Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The financial burden of cancer treatment and how to address it

Michael Hallek • 9 Jun 2016
EHA 2016
General

Michael Hallek, MD from the University of Cologne, Cologne, Germany talks about the issue of drug cost in oncology. According to Prof. Hallek, this is a political problem and an economic burden for society. He argues that politicans, companies, health insurers and patients need to work together proactively anf find a solution to make sure, that combination therapies are affordable everywhere in the world.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Michael Hallek

BCL-2 frontline therapy in CLL
2:24
BCL-2 frontline therapy in CLL
Michael Hallek • 25 Aug 2020
Updates from the German CLL Study Group
3:53
Updates from the German CLL Study Group
Michael Hallek • 28 Aug 2020
Treating highly relapsed/refractory CLL
3:02
Treating highly relapsed/refractory CLL
Michael Hallek • 27 Aug 2020
Value of MRD measurement in CLL
2:32
Value of MRD measurement in CLL
Michael Hallek • 27 Aug 2020

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals